Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 maintenance and flare-reduction study of once-daily crisaborole ointment in mild to moderate atopic dermatitis responders
MOH_2020-02-09_008680Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Once-daily crisaborole maintenance with Once-daily placebo maintenance (2 arms). Primary endpoints: Long-term efficacy of maintenance treatment and Long-term safety and local tolerability. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
crisaborole
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2020-02-09_008680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-02-09_008680.